Jaguar Animal Health (NASDAQ:JAGX) has climbed 6.97% in the past week and advanced 53.57% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 8.25% and the outperformance has advanced to 52.17% for the last 4 weeks period.
Jaguar Animal Health (NASDAQ:JAGX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.83 and $2.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.15, notching a gain of 11.40% for the day. The total traded volume was 2,615,453 . The stock had closed at $1.93 on the previous day.
On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Jaguar Animal Health, Inc., Bochnowski James J had purchased shares worth of $400,000 in a transaction dated on February 8, 2016. A total of 160,000 shares were purchased at a price of $2.5 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Institutional Investors own 29.69% of Jaguar Animal Health shares.
Jaguar Animal Health, Inc. is a development-stage animal health company focused on developing and commercializing gastrointestinal products for companion and production animals. The Companys pipeline of prescription drug product candidates includes Canalevia, species-specific formulations of crofelemer, Virend and species-specific formulations of NP-500. The Companys non-prescription products comprises of Neonorm Calf and species-specific formulations of Neonorm. Canalevia is the lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. The Company develops Virend for the treatment of herpes virus in cats. Neonorm Calf is used to improve gut health and normalize stool formation in preweaned dairy calves with scours.